Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Ribomustin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the… Expand
2015
2015
Thomas Mehrling was appointed Managing Director of Mundipharma EDO GmbH, Basel, in January 2013 and brings extensive experience… Expand
Review
2011
Review
2011
  • N. Tageja
  • Clinical Medicine Insights. Oncology
  • 2011
  • Corpus ID: 11645510
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients… Expand
  • table 1
  • table 2
Review
2010
Review
2010
BackgroundBendamustine (Treanda, Ribomustin) is a water-soluble, bifunctional chemotherapeutic agent that also has potential… Expand
  • table 1
  • table 2
  • figure 1
2010
2010
Bendamustine for indolent NHL was assessed in three phase III trials, it was assessed in one phase III trial for patients with… Expand
Review
2010
Review
2010
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia type in adults. Despite significant achievements in therapy of… Expand
Review
2009
Review
2009
BACKGROUND Bendamustine is a mechlorethamine derivative with a purine-like benzimidazole ring, which may enhance its clinical… Expand
Review
2008
Review
2008
Bendamustine (Treanda, Ribomustin) is a bifunctional alkylating agent that also has potential antimetabolite properties, and only… Expand
Review
2002
Review
2002
  • V. Gandhi
  • Seminars in oncology
  • 2002
  • Corpus ID: 42669843
Bendamustine hydrochloride is the active ingredient of Ribomustin (Ribosepharm GmbH, Munich, Germany). It was first synthesized… Expand